Across TCGA pan-cancer cohorts, TRAJ61 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRAJ61 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TRAJ61 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TRAJ61 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where TRAJ61 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	1.000	0.486	.030	6	view →
HNSC	DFS	Median	II,III,IV	0.825	1.000	.041	4	view →
CCRCC	OS	Median	IV	1.000	0.451	.016	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TRAJ61 tumor-vs-normal RNA expression · all TRAJ61 data types